Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Dec 23, 2022
Neuren submits IND & first patients complete Phase 2 trials
Dec 07, 2022
Becoming a substantial holder
Dec 02, 2022
Ceasing to be a substantial holder
Nov 23, 2022
Change in substantial holding
Oct 27, 2022
Q3 2022 quarterly activity and cash flow report
Oct 20, 2022
Neuren receives US$10 million milestone payment
Sep 14, 2022
Investor presentation, 14 September 2022
Sep 13, 2022
Rett Syndrome NDA accepted for Priority Review by FDA
Aug 24, 2022
Half-year shareholder update
Aug 24, 2022
Half Yearly Report and Accounts
1
2
3
4
Next
